These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Antihypertensive efficacy of the angiotensin II AT1-receptor antagonist losartan: results of a randomized, double-blind, placebo-controlled, parallel-group trial using 24-hour blood pressure monitoring. Ambulatory Blood Pressure Monitoring Study Group.
    Author: Byyny RL.
    Journal: Blood Press Suppl; 1996; 2():71-7. PubMed ID: 8913544.
    Abstract:
    The antihypertensive efficacy of once- and twice-daily losartan was evaluated in a randomized, double-blind, placebo-controlled, parallel-group trial using ambulatory 24-h blood pressure monitoring in 122 patients with mild to moderate essential hypertension. Data are reported for 112 patients who completed the active treatment phase. Losartan exerted a sustained 24-h antihypertensive effect at all doses studied (50 or 100 mg once daily, or 50 mg twice daily). Losartan demonstrated a smooth, gradual onset of action, did not affect normal circadian variations on blood pressure, and had no significant effect on heart rate. An additive antihypertensive effect was obtained by adding low-dose hydrochlorothiazide to losartan monotherapy at all doses of losartan studied. Losartan was well tolerated during the study with a frequency of adverse events comparable with placebo. No major adverse events were recorded. The results of this study indicate that losartan is an effective and well-tolerated antihypertensive agent that provides 24-h blood pressure-lowering efficacy from a single daily dose of 50 mg.
    [Abstract] [Full Text] [Related] [New Search]